Royal Philips (NYSE: PHG, AEX: PHIA), announced it has supported the NHS' Cheshire and Merseyside consortium [1] to become the first regional hub supplying the United Kingdom's National COVID-19 Chest Imaging Database (NCCID). The NCCID is a centralized database containing X-Ray, CT and MRI images from hospital patients across the country. 
Oxehealth has announced another world first after the US Food and Drug Administration granted a De Novo clearance for its Oxehealth Vital Signs product, which is incorporated into Oxevision, the vision-based patient monitoring and management platform delivered as software as a service. Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Orbita Inc., an innovative provider of conversational artificial intelligence (AI) solutions for healthcare, announced a partnership agreement to co-create next-generation conversational virtual assistants for Philips' consumer health and patient support applications. 
CliniSys Group has created a single brand for its businesses in the UK and Europe, with a refreshed logo and a new website.
The move creates a unified identity for CliniSys in the UK and MIPS on the continent and underlines the group's commitment to providing end-to-end diagnostic systems to support safe and effective healthcare systems today and to drive medical innovation in the future.
Thousands of NHS professionals across five hospitals in East Lancashire are to benefit from early warning technology that will help them detect and swiftly respond to deteriorating patients in need of urgent attention.
Alcidion's Patientrack system will help staff intervene early to prevent harm when patients show signs of worsening conditions.
Moderna (Nasdaq: MRNA) and IBM (NYSE: IBM) announced their intentions to explore technologies, including artificial intelligence, blockchain and hybrid cloud, that could help support smarter COVID-19 vaccine management. Central to the effort will be a pilot of open, standardized, technology-enabled vaccine distribution approaches aimed to improve supply chain visibility and foster near real-time tracking of vaccine administration. 
Elsevier, together with Boehringer Ingelheim, Eli Lilly and Company, Pierre Fabre, Sanofi, Servier and others, has further refined and extended its drug-drug interaction risk calculator (DDIRC) within PharmaPendium. The DDIRC 2.0 aims to help scientists improve patient safety and effectively manage drug-drug interaction (DDI) risks across the drug development process.